Trial Profile
A Phase 3b/4, Prospective, Multicenter, Open-label, Randomized, Crossover Study of Tolerability and Safety of FEIBA Reconstituted in Regular or 50% Reduced Volume and of Faster Infusion Rates in Patients With Hemophilia A or B With Inhibitors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Factor VIII inhibitor bypassing fraction (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; Registrational
- Acronyms FEIBA STAR
- Sponsors Baxalta; Shire; Takeda
- 20 Jan 2022 Status changed from active, no longer recruiting to completed.
- 06 Dec 2021 Planned End Date changed from 31 Oct 2021 to 15 Dec 2021.
- 06 Dec 2021 Planned primary completion date changed from 31 Oct 2021 to 15 Dec 2021.